| For: | Savaliya BP, Shekouhi R, Mubarak F, Manaise HK, Jimenez PB, Kowkabany G, Popp RA, Popp K, Gabriel E. Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors. World J Gastroenterol 2024; 30(24): 3052-3058 [PMID: 38983963 DOI: 10.3748/wjg.v30.i24.3052] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i24/3052.htm |
| Number | Citing Articles |
| 1 |
Occurrence of hepatitis B and C infection in pediatric patients with cancer at Alhadbaa Hospital in Mosul/Iraq. Iraqi Journal of Cancer and Medical Genetics 2025; 18(2) doi: 10.29409/20hcxw96
|
| 2 |
Xiaohuan Zhou, Yi Feng, Jie Liang, Xin Bi, Qiu Zhong, Lipeng Xue, Jieshuo Wang, Jianxing He, Liping Liu, Bo Cheng, Wenhua Liang. Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study. Lung Cancer 2026; doi: 10.1016/j.lungcan.2026.109554
|
| 3 |
Yurou Jin, Chao Jin, Ronghui Xie, Jingming Zhang, Guangmin Wei, Ling Zheng. HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1765054
|
| 4 |
Alla A. Kushch. Occult hepatitis B: prevalence and clinical significance. Role in liver pathology and in viral coinfections. Problems of Virology 2025; 70(4) doi: 10.36233/0507-4088-291
|